Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma.
Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, Kilcoyne A, Giles FJ, Nelon LD, Carew JS, Ouyang Y, Michalek JE, Pal R, Druker BJ, Rubin BP, Keller C. Abraham J, et al. Among authors: loriaux mm. Biochem Biophys Res Commun. 2012 Sep 28;426(3):363-8. doi: 10.1016/j.bbrc.2012.08.092. Epub 2012 Aug 30. Biochem Biophys Res Commun. 2012. PMID: 22960170 Free PMC article.
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.
Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM. Tyner JW, et al. Among authors: loriaux mm. Cancer Res. 2013 Jan 1;73(1):285-96. doi: 10.1158/0008-5472.CAN-12-1906. Epub 2012 Oct 18. Cancer Res. 2013. PMID: 23087056 Free PMC article.
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, Loriaux MM. Spurgeon SE, et al. Among authors: loriaux mm. J Pharmacol Exp Ther. 2013 Feb;344(2):378-87. doi: 10.1124/jpet.112.200832. Epub 2012 Dec 7. J Pharmacol Exp Ther. 2013. PMID: 23220742 Free PMC article.
A case study of personalized therapy for osteosarcoma.
Davis LE, Hofmann NE, Li G, Huang ET, Loriaux MM, Bracha S, Helfand SC, Mata JE, Marley K, Mansoor A, Tyner JW, Abraham J, Séguin B, Keller C. Davis LE, et al. Among authors: loriaux mm. Pediatr Blood Cancer. 2013 Aug;60(8):1313-9. doi: 10.1002/pbc.24512. Epub 2013 Mar 22. Pediatr Blood Cancer. 2013. PMID: 23526721
Therapeutically Targetable ALK Mutations in Leukemia.
Maxson JE, Davare MA, Luty SB, Eide CA, Chang BH, Loriaux MM, Tognon CE, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW. Maxson JE, et al. Among authors: loriaux mm. Cancer Res. 2015 Jun 1;75(11):2146-50. doi: 10.1158/0008-5472.CAN-14-1576. Cancer Res. 2015. PMID: 26032424 Free PMC article.
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Prins RC, Burke RT, Tyner JW, Druker BJ, Loriaux MM, Spurgeon SE. Prins RC, et al. Among authors: loriaux mm. Leukemia. 2013 Oct;27(10):2094-6. doi: 10.1038/leu.2013.228. Epub 2013 Jul 31. Leukemia. 2013. PMID: 23900138 No abstract available.
79 results